/DO NOT DISTRIBUTE TO U.S. NEWS WIRE AGENCIES OR PUBLISH, DISTRIBUTE OR DISSEMINATE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO THE UNITED STATES (USA)/
TORONTO, Aug. 24, 2018 /CNW Telbec/ - LiveWell Canada Inc. ("LiveWell" or the "Company"), (TSXV: LVWL), is pleased to announce the publishing of white paper on Cannabidiol (CBD) from Industrial Hemp. "Given the rapid emergence of interest in CBD, but relative lack of information, we thought it would be helpful to summarize our findings to provide context to our stakeholders regarding its health benefits and the CBD market," commented David Rendimonti, President. "From the data assembled thus far, we believe that we are just scratching the surface as to the global opportunity in CBD from industrial hemp."
The following is an excerpt from the report:
"There has been surge of interest in CBD in recent years given a growing body of evidence as to CBD's positive health effects including: pain relief, combatting mood disorders, lowering inflammation, etc. CBD is a non-psychoactive compound found in cannabis and hemp, meaning it doesn't have the effect of getting a person high. The chemical composition of CBD from both plants is identical, however, CBD from industrial hemp is cheaper to produce and has a far less restrictive legal framework allowing for wider adoption at a faster pace. Most recently the U.S. Food and Drug Administration (FDA) just approved the first CBD-based drug to treat epileptic seizures called Epidiolex. The evidence as to its health keeps building every day. This is a rapidly emerging market that could have CBD in many of the products people consume on a daily basis."
About LiveWell Canada LiveWell Canada Inc. (TSX-V:LVWL) is an innovative Canadian company planning to become a leader in a new approach to health and wellness by conducting advanced studies on cannabidiol (CBD) and other cannabinoids in its world-class Research and Innovation Centre located in Litchfield, Québec. The company's mission also includes developing and distributing prescription and consumer health products. With more than 1.5 million square feet of greenhouses under construction located in Ontario and Québec, the company is supported by renowned academic and business partners such as Canopy Growth (TSX:WEED, NYSE:CGC) and Canopy Rivers. For more information, visit livewellcorp.com
This release includes forward-looking statements about the Company and its business. Often, but not always, forward-looking statements can be identified by the use of words such as "plan", "continue", "expect", "schedule", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements (including negative variations) that certain events or conditions "may" or "will" occur.Such statements are based on the current expectations of management. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of unknown and known risk factors and uncertainties affecting the Company, including risks regarding the cannabis and hemp industry, economic factors, the equity markets and risks associated with growth and competition. The Company cautions that this foregoing list of material factors is not exhaustive, and readers are encouraged to read all Risk Factors disclosed in the Company's Filing Statement dated May 29, 2018.
The forward-looking information contained in this press release represents expectations of the Company as of the date of this press release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable securities laws.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.